Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Charles Cantor, William Kelly, Sandeep Reddy

Premium

Charles Cantor has joined InSilico Medicine's scientific advisory board and will serve as its chair. Cantor co-founded Sequenom and is a professor emeritus at Boston University, distinguished adjunct professor at the University of California, Irvine, and an adjunct professor at the Moscow Institute of Physics and Technology and also at Scripps Research Institute. He was previously the chair and professor of the department of biomedical engineering and biophysics and director of the Center for Advanced Biotechnology at Boston University.


Exosome Diagnostics has named William Kelly as CFO.

Kelly has worked for RepliGen for the past six years, serving as the principal financial officer there for more than five years. He has also served as corporate controller of Haemonetics, and has worked for Deloitte & Touche.


Caris Life Sciences has promoted Sandeep Reddy to chief medical officer. He was previously senior medical director at Caris. In his new role, he will lead the company's research efforts through the Caris Research Institute and guide strategy for the deployment of Caris' precision medicine tools in the clinical setting.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.